Atlas Venture Life Science Advisors
Latest statistics and disclosures from Atlas Venture Life Science Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are DYN, KYMR, THRD, IRON, DAWN, and represent 82.79% of Atlas Venture Life Science Advisors's stock portfolio.
- Added to shares of these 3 stocks: IRON (+$10M), TECX (+$6.2M), KRRO.
- Started 1 new stock position in TECX.
- Reduced shares in these 6 stocks: AVRO (-$5.8M), DNTH, XLO, KYMR, AVTE, SPRO.
- Sold out of its positions in AVRO, XLO.
- Atlas Venture Life Science Advisors was a net buyer of stock by $7.4M.
- Atlas Venture Life Science Advisors has $950M in assets under management (AUM), dropping by -12.36%.
- Central Index Key (CIK): 0001917529
Tip: Access up to 7 years of quarterly data
Positions held by Atlas Venture Life Science Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Atlas Venture Life Science Advisors
Atlas Venture Life Science Advisors holds 15 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Dyne Therapeutics Common Stock (DYN) | 29.8 | $283M | 8.0M | 35.29 |
|
|
| Kymera Therapeutics Common Stock (KYMR) | 16.8 | $160M | 5.4M | 29.85 |
|
|
| Third Harmonic Bio Common Stock (THRD) | 14.9 | $142M | 11M | 13.00 |
|
|
| Disc Medicine Common Stock (IRON) | 11.9 | $113M | +9% | 2.5M | 45.07 |
|
| Day One Biopharmaceuticals Common Stock (DAWN) | 9.3 | $89M | 6.4M | 13.78 |
|
|
| Korro Bio Common Stock (KRRO) | 4.1 | $39M | 1.1M | 33.87 |
|
|
| Q32 Bio Common Stock (QTTB) | 4.0 | $38M | 2.1M | 17.95 |
|
|
| Generation Bio Common Stock (GBIO) | 2.5 | $23M | 8.3M | 2.82 |
|
|
| Vigil Neuroscience Common Stock (VIGL) | 2.5 | $23M | 5.8M | 4.00 |
|
|
| Replimune Group Common Stock (REPL) | 2.0 | $19M | 2.1M | 9.00 |
|
|
| Ikena Oncology Common Stock (IKNA) | 0.9 | $8.3M | 5.0M | 1.65 |
|
|
| Tectonic Therapeutics Common Stock (TECX) | 0.7 | $6.2M | NEW | 378k | 16.47 |
|
| Dianthus Therapeutics Common Stock (DNTH) | 0.4 | $3.5M | -26% | 137k | 25.88 |
|
| Aerovate Therapeutics Common Stock (AVTE) | 0.3 | $3.0M | -11% | 1.8M | 1.66 |
|
| Spero Therapeutics Common Stock (SPRO) | 0.1 | $696k | -11% | 535k | 1.30 |
|
Past Filings by Atlas Venture Life Science Advisors
SEC 13F filings are viewable for Atlas Venture Life Science Advisors going back to 2022
- Atlas Venture Life Science Advisors 2024 Q2 filed Aug. 9, 2024
- Atlas Venture Life Science Advisors 2024 Q1 filed May 6, 2024
- Atlas Venture Life Science Advisors 2023 Q4 filed Feb. 9, 2024
- Atlas Venture Life Science Advisors 2023 Q3 filed Nov. 13, 2023
- Atlas Venture Life Science Advisors 2023 Q2 filed Aug. 11, 2023
- Atlas Venture Life Science Advisors 2023 Q1 filed May 15, 2023
- Atlas Venture Life Science Advisors 2022 Q4 filed Feb. 14, 2023
- Atlas Venture Life Science Advisors 2022 Q3 filed Nov. 9, 2022
- Atlas Venture Life Science Advisors 2022 Q2 filed Aug. 3, 2022
- Atlas Venture Life Science Advisors 2021 Q4 filed May 16, 2022
- Atlas Venture Life Science Advisors 2022 Q1 filed May 16, 2022